Rocket Pharma Scores Fast-Track Voucher for Kids' Rare Disease Drug
Published Date: 4/2/2026
Notice
Summary
The FDA just gave Rocket Pharmaceuticals a special priority review voucher for their rare pediatric disease treatment, KRESLADI, approved on March 26, 2026. This voucher speeds up future FDA reviews, helping get important medicines to kids with rare diseases faster. It’s a big win for patients, the company, and anyone cheering for quicker cures!
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Priority Review Voucher Awarded
The FDA issued a priority review voucher to Rocket Pharmaceuticals for KRESLADI, with the drug approved on March 26, 2026. The voucher can be used to obtain a faster FDA review for a future drug application under the Rare Pediatric Disease Priority Review Voucher Program.
New Pediatric Treatment Approval
A new treatment, KRESLADI (marnetegragene autotemcel), was approved on March 26, 2026 for pediatric patients with severe leukocyte adhesion deficiency-I (LAD‑I) caused by biallelic ITGB2 variants when an HLA‑matched sibling donor for transplant is not available. If you have a child with this condition, this approval adds an FDA‑approved treatment option.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in